At this year’s EAU (European Association of Urology) meeting in Munich, March 11-15, a German multi-center study on UBC® Rapid was presented. Responsible for the study was Dr Thorsten Ecke, Helios Hospital, Department of Urology, Bad Sarrow. Urine samples were analyzed by UBC®Rapid POC test and evaluated quantitatively. The study showed very high sensitivity and specificity for high grade tumors generally 71/94%, and for CIS patients the sensitivity was even higher 87%.The authors concluded that UBC® Rapid should be added in the diagnostics for high risk bladder cancer and in particular for CIS patients with tumors in the bladder.
For further information, please contact:
Vice President Sales & Marketing
IDL Biotech AB (publ)
+46 8 799 67 50